How to Get Rezdiffra (Resmetirom) in Oklahoma

What Is Rezdiffra and Why Does It Matter for Oklahoma Patients?

Rezdiffra (resmetirom) is the first FDA-approved drug specifically targeting MASH, a progressive liver disease formerly called non-alcoholic steatohepatitis (NASH). The FDA granted accelerated approval in March 2024 based on the MAESTRO-NASH phase 3 trial, which enrolled 966 patients with biopsy-confirmed MASH and fibrosis stages F1B through F3 [1]. At 52 weeks, 25.9% of patients receiving the 80 mg dose achieved MASH resolution with no worsening of fibrosis, compared to 9.7% on placebo.

Oklahoma carries a disproportionate burden of liver disease risk factors. The state ranks among the top 15 nationally for adult obesity prevalence, with rates exceeding 36% according to CDC data [2]. An estimated 1.5% to 6.5% of U.S. adults have MASH, per the American Association for the Study of Liver Diseases [3], and Oklahoma's metabolic disease profile suggests the state sits toward the higher end of that range. Rural access gaps across much of western and southeastern Oklahoma make telehealth pathways and pharmacy logistics especially relevant for patients seeking this treatment.

Telehealth Prescribing of Rezdiffra in Oklahoma

Oklahoma law permits telehealth prescribing of Rezdiffra. The state does not impose a prior in-person visit requirement for establishing a prescriber-patient relationship via synchronous audio-video consultation. This means a board-certified hepatologist or gastroenterologist licensed in Oklahoma can evaluate, diagnose, and prescribe resmetirom remotely.

Several conditions apply. The prescriber must hold an active Oklahoma medical license or be authorized through an interstate compact. A documented clinical evaluation, including review of imaging, lab values, and liver biopsy results (or validated noninvasive markers), must be completed before prescribing. The FDA-approved prescribing information specifies that Rezdiffra is indicated for adults with MASH and moderate to advanced hepatic fibrosis (consistent with stages F2-F3), which the telehealth clinician must confirm [4].

Telehealth is particularly valuable for patients in rural Oklahoma counties. Only a handful of hepatology practices operate outside the Oklahoma City and Tulsa metro areas. A patient in Altus or McAlester, for example, may face a 150+ mile drive to see a specialist in person. Telehealth collapses that barrier to a video visit, though the patient still needs local access to labs and, if required, FibroScan or liver biopsy facilities.

Who Can Prescribe Rezdiffra in Oklahoma?

Any clinician with independent prescriptive authority in Oklahoma can write a Rezdiffra prescription. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Oklahoma grants full practice authority to NPs who hold an APRN license, which means NPs can prescribe resmetirom without physician oversight per the Oklahoma Board of Nursing [5].

Practically, though, most prescriptions originate from hepatologists and gastroenterologists. The drug's indication requires confirmed MASH with fibrosis staging, a diagnostic workup that primary care providers can initiate but rarely complete independently. A common workflow: the PCP identifies elevated ALT, orders a FibroScan or FIB-4 calculation, and refers to a GI specialist who confirms the diagnosis and writes the prescription.

PAs in Oklahoma prescribe under a collaborative agreement with a supervising physician. While the PA can write the prescription, the supervising physician's DEA and license information may need to appear on prior authorization paperwork depending on the insurer.

Required Labs and Diagnostic Workup Before Prescribing

Before initiating Rezdiffra, Oklahoma providers typically order a specific panel of labs and assessments. The FDA label and clinical practice patterns from the MAESTRO-NASH protocol establish the following baseline requirements [1][4]:

Mandatory or near-universal labs:

• Comprehensive metabolic panel (CMP), including ALT, AST, alkaline phosphatase, and bilirubin
• Lipid panel (resmetirom is a thyroid hormone receptor-beta agonist that lowers LDL cholesterol)
• Thyroid function tests (TSH, free T4) to rule out uncontrolled thyroid disease
• Complete blood count (CBC)
• INR/PT if cirrhosis is suspected

Fibrosis staging:

• FibroScan (vibration-controlled transient elastography) with a liver stiffness measurement of 8.0 kPa or above generally suggests F2+ fibrosis
• FIB-4 index as a screening tool (calculated from age, AST, ALT, and platelet count)
• Liver biopsy remains the gold standard, though many insurers now accept noninvasive alternatives for prior authorization

Imaging:

• Abdominal ultrasound or MRI-PDFF to document hepatic steatosis

In the MAESTRO-NASH trial, patients were required to have a liver biopsy confirming MASH with a NAFLD Activity Score (NAS) of 4 or greater and fibrosis stage F1B to F3 [1]. Some commercial insurers in Oklahoma mirror this biopsy requirement for prior authorization. Others accept a combination of FibroScan results plus elevated ALT as sufficient documentation.

Labs can be drawn at any Quest Diagnostics, LabCorp, or hospital-based lab in Oklahoma. FibroScan availability is more limited. Facilities offering FibroScan include major medical centers in Oklahoma City (OU Health, Integris, SSM Health St. Anthony) and Tulsa (Saint Francis, Ascension St. John). Patients in rural areas may need to travel for this specific test.

Insurance Coverage and Prior Authorization in Oklahoma

Coverage for Rezdiffra varies sharply by payer type in Oklahoma. The commercial list price exceeds $40,000 per year, making insurance coverage a practical necessity for most patients.

Oklahoma Medicaid: Does not cover Rezdiffra as of 2026. Patients enrolled in SoonerCare (Oklahoma's Medicaid program) currently have no formulary pathway to the drug. Madrigal Pharmaceuticals offers a patient assistance program that may provide the drug at no cost to qualifying uninsured or underinsured patients.

Commercial insurance: Most major plans operating in Oklahoma (Blue Cross Blue Shield of Oklahoma, UnitedHealthcare, Aetna, Cigna) have added Rezdiffra to specialty tiers with mandatory prior authorization. According to a 2024 analysis in the Journal of Managed Care & Specialty Pharmacy, early payer coverage decisions for resmetirom consistently required documentation of MASH diagnosis, fibrosis staging, and failure or contraindication to lifestyle interventions [6].

Medicare Part D: Coverage varies by plan. Patients should verify formulary status with their specific Part D plan. Some plans have added Rezdiffra with step therapy requirements.

Prior authorization documentation typically includes:

• Clinical diagnosis of MASH (ICD-10 code K75.81)
• Fibrosis stage documentation (biopsy report, FibroScan results, or FIB-4 score)
• Evidence that the patient has attempted lifestyle modifications (diet and exercise)
• BMI and metabolic comorbidity documentation
• Prescriber specialty credentials
• Lab results (ALT, AST, lipid panel, thyroid function)

The prior authorization process takes 5 to 15 business days for most Oklahoma commercial plans. Denials can be appealed. The most common denial reason is insufficient fibrosis documentation, which is resolvable by submitting FibroScan or biopsy results.

Pharmacy Access and Fulfillment in Oklahoma

Rezdiffra is classified as a specialty medication. It is not stocked at standard retail pharmacies like Walgreens or CVS. Oklahoma patients typically receive the drug through one of three channels.

Specialty pharmacies: National specialty pharmacy networks (Optum Specialty, CVS Specialty, Accredo, AllianceRx Walgreens Prime) fulfill Rezdiffra prescriptions and ship directly to Oklahoma addresses. Turnaround after prior authorization approval is usually 3 to 7 business days. Some Oklahoma-based specialty pharmacies, including those affiliated with OU Health and Saint Francis, may also carry the drug.

503A compounding pharmacies: Oklahoma licenses 503A compounding pharmacies that can prepare resmetirom formulations pursuant to a valid patient-specific prescription. This pathway is primarily relevant for patients who need dose adjustments or alternative formulations not available commercially. The Oklahoma State Board of Pharmacy regulates these facilities. A 503A pharmacy compounds for an individual patient based on a prescription, as distinct from 503B outsourcing facilities that produce larger batches. Patients should confirm that their specific 503A pharmacy sources resmetirom API from an FDA-registered supplier.

Mail-order: Most specialty pharmacy fulfillment is mail-order by default. Packages require signature and temperature-controlled shipping is used during summer months, which matters in Oklahoma where temperatures regularly exceed 100°F from June through August.

Timeline: Prescription to First Dose

The total time from initial clinical evaluation to receiving Rezdiffra in Oklahoma breaks down roughly as follows:

Week 1: Initial consultation (telehealth or in-person). Labs ordered and drawn. If FibroScan is needed, scheduling may add 1 to 2 weeks depending on location.

Weeks 2-3: Lab and imaging results reviewed. Prescriber confirms MASH with F2-F3 fibrosis. Prescription submitted to specialty pharmacy. Prior authorization initiated.

Weeks 3-5: Prior authorization decision (5-15 business days). If approved, pharmacy dispenses and ships within 3-7 days. If denied, appeal adds another 2-4 weeks.

Best case: 7 to 10 days for patients with existing diagnostic workup and a cooperative insurer. Typical case: 14 to 21 days. Worst case: 6 to 8 weeks if prior authorization is denied and appealed.

Patients with a recent liver biopsy or FibroScan already on file can compress this timeline significantly. Bringing prior records to the initial consultation, whether telehealth or in-person, eliminates the diagnostic delay.

Dosing and Monitoring After Starting Rezdiffra

Per the FDA prescribing information, the recommended starting dose is 80 mg once daily for patients with a BMI <30 kg/m², or 100 mg once daily for patients with BMI of 30 or above [4]. The tablet is taken with food.

Monitoring requirements during treatment include:

• Liver enzymes (ALT, AST): Check at baseline, then every 3 months for the first year. The MAESTRO-NASH trial reported ALT reductions averaging 15-20% from baseline with resmetirom versus placebo [1].
• Lipid panel: LDL cholesterol drops are expected and clinically significant. In MAESTRO-NASH, LDL fell by approximately 14% with the 80 mg dose at 52 weeks [1]. Patients on statins may need dose adjustments.
• Thyroid function: TSH and free T4 at baseline and 6 months. Resmetirom is selective for thyroid hormone receptor-beta (THR-β), which is predominantly expressed in the liver, so systemic thyroid effects are minimal but should be monitored.
• Weight and metabolic parameters: Body weight changes were modest in clinical trials, with no statistically significant difference from placebo in the primary analysis.

Oklahoma providers should be aware that the Endocrine Society's 2024 guidance on THR-β agonists recommends monitoring for diarrhea and nausea during the first 4 weeks of therapy, as these were the most commonly reported adverse events in MAESTRO-NASH (occurring in approximately 10-12% of treated patients versus 6-8% on placebo) [7][1].

Transferring a Rezdiffra Prescription to Oklahoma

Patients relocating to Oklahoma from another state can transfer an existing Rezdiffra prescription. Oklahoma accepts prescription transfers from all 50 states under standard Board of Pharmacy regulations. The originating pharmacy contacts the receiving Oklahoma specialty pharmacy to complete the transfer.

Two practical considerations. First, prior authorization does not transfer between insurance plans. If the move involves a change in insurance (for example, from a Texas Blue Cross plan to an Oklahoma employer plan), a new prior authorization must be submitted. Second, some specialty pharmacies operate nationally and can simply update the shipping address without a formal transfer. Patients should call their current specialty pharmacy before initiating a transfer to check whether a ship-to-address change is the simpler path.

Cost Without Insurance in Oklahoma

The wholesale acquisition cost (WAC) for Rezdiffra is approximately $47,400 per year. Patients paying out of pocket face monthly costs exceeding $3,900. Madrigal Pharmaceuticals operates the Rezdiffra Complete support program, which includes:

• A copay assistance card reducing out-of-pocket costs to as low as $0 per month for commercially insured patients
• A patient assistance program providing the drug at no cost to uninsured patients who meet income criteria (typically <400% of the federal poverty level, which is approximately $62,400 for a single individual in 2026)

Patients can enroll at the manufacturer's support program website or by calling the number on the program's materials. Oklahoma providers and specialty pharmacies can also initiate enrollment on the patient's behalf.

The MASH-related economic burden is substantial independent of drug costs. A 2023 analysis published in Hepatology Communications estimated annual direct healthcare costs for MASH patients at $5,300 to $8,600 higher than matched controls, driven primarily by liver-related hospitalizations and comorbidity management [8]. Treatment that resolves MASH histology and halts fibrosis progression may reduce these downstream costs.